Agilent Technologies (Oligo GMP)

Santa Clara, CA
Reagent / Material Supplier
1 confirmed programs · 1 sponsors · Last scored 2026-04-29
74.2
Signal Score
✓ FDA Inspections (2) ✓ Clinical Trials (1) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Agilent Technologies (Oligo GMP)

Signal Score
74.2/100 (as of 2026-04-29)
Quality Compliance
100.0/100
Headquarters
Santa Clara, CA
Modalities
Oligonucleotide
Active Programs
1 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Agilent Technologies (Oligo GMP)

Reagent/raw material supplier.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA Inspections2 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2026-05-06)
Operations 60.0
1 active programs across 1 sponsors
Modalities: Oligonucleotide
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
1 active programs across 1 sponsors · Modalities: Oligonucleotide · 1 programs in advanced phases (Phase 2/3)
Programs 1
Sponsors1
ModalitiesOligonucleotide
1 active programs across 1 sponsors
Modalities: Oligonucleotide
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT02452697 Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From... PHASE2 Unknown
Source: ClinicalTrials.gov · Retrieved Jul 04, 2026
Financial Stability 68.0
Parent company: Agilent Technologies
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Agilent Technologies
Financial assessment: 68.0/100
Capacity 53.0
1 manufacturing site: Boulder, CO
Modalities: Oligonucleotide
Capacity assessment: 53.0/100
Sites: Boulder, CO
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Boulder, CO
Modalities: Oligonucleotide
Capacity assessment: 53.0/100

Agilent Technologies (Oligo GMP) FDA Inspection History

2026-05
2025-06
NAI VAI OAI
Date Site Type Observations Classification
2026-05-06 Boulder, Colorado Drug Quality Assurance No No Action Indicated (NAI)
2025-06-18 Frederick, Colorado Drug Quality Assurance No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Jul 04, 2026

Clinical Activity 1 studies

Source: ClinicalTrials.gov · Retrieved Jul 04, 2026

Frequently Asked Questions About Agilent Technologies (Oligo GMP)

How many FDA inspections does Agilent Technologies (Oligo GMP) have on record?
CDMO Signal tracks 2 FDA inspections for Agilent Technologies (Oligo GMP), sourced from the FDA inspection database. See the full inspection history above.
Has Agilent Technologies (Oligo GMP) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Agilent Technologies (Oligo GMP).
How many clinical programs is Agilent Technologies (Oligo GMP) linked to?
Agilent Technologies (Oligo GMP) is associated with 1 clinical trial in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Agilent Technologies (Oligo GMP)'s CDMO Signal Score?
Agilent Technologies (Oligo GMP) has a Signal Score of 74/100, based on quality, operations, financial stability, and capacity data.
Evaluating Agilent Technologies (Oligo GMP) for a manufacturing program?
Use the free AI matchmaker to compare Agilent Technologies (Oligo GMP) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Oligonucleotide CDMOs →

Similar CDMOs

Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 85.6
Oligonucleotide, Biologics, AAV
TriLink BioTechnologies
San Diego, CA
Signal Score: 71.0
mRNA, Oligonucleotide
PolyPeptide Group
Torrance, CA · Strasbourg, FR · Malmo, SE
Signal Score: 64.8
Oligonucleotide
LGC Biosearch Technologies
Petaluma, CA · Middleton, WI
Signal Score: 63.0
Oligonucleotide
Hongene Biotech
Union City, CA
Signal Score: 56.5
Oligonucleotide